Published online Oct 10, 2018. doi: 10.5527/wjn.v7.i6.123
Peer-review started: June 4, 2018
First decision: July 11, 2018
Revised: August 2, 2018
Accepted: August 30, 2018
Article in press: August 30, 2018
Published online: October 10, 2018
The effect of phosphate binders in clinically important outcomes, such as metabolic acidosis, remains understudied.
There are no studies examining the effect of the novel phosphate binder sucroferric oxyhydroxide (SFOH) on acid-base status.
Examine possible alterations in acid-base parameters in hemodialysis patients switching from lanthanum carbonate (LanC) to SFOH.
Fifteen stable hemodialysis patients switched from LanC to SFOH. We compared pre- and post-switching blood gas analyses, whilst hemodialysis conditions and medications remained stable.
Switching from LanC to the novel phosphate binder SFOH did not have any significant effect on blood bicarbonate levels and gas analysis. No correlations were found, either between pre-switching LanC daily dose or between post-switching daily dose of the new binder and the measured parameters.
This is the first study that evaluates acid-base status in patients switching from LanC to the new phosphate binder SFOH, showing that there is no need to change hemodialysis prescription regarding these parameters.
Our study can serve as a pilot for further studies with a larger number of patients, different binders and extended durations, to better understand their effect in clinically important outcomes, such as metabolic acidosis.